Several studies reported the use of TCR-engineered T cells to treat patients including NY-ESO-1-directed tTCR and MAGE-A3-directed tTCR for multiple myeloma (MM) (5, 6), and WT1-directed tTCR for acute myeloid leukemia (AML) (7). Here, MAGEA3 is linked to acute myeloid leukemia.